Impact of Health Insurance Coverage on Diabetes Care Quality: A Systematic Review and Meta-analysis of Racial, Ethnic, and Gender Disparities in U.S. Adults with Type 2 Diabetes.

J Gen Intern MedJun 30, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Pengfei Gao

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of health insurance coverage on diabetes care quality among U.S. adults with type 2 diabetes. It found that insurance significantly increased the likelihood of HbA1c testing (β = 0.2683, p = 0.0145), but did not eliminate racial, ethnic, or gender disparities in care quality.

Key findings

  • Insurance coverage significantly increased the likelihood of HbA1c testing (β = 0.2683, p = 0.0145).
  • No statistically significant associations were found for blood pressure control, eye examinations, or LDL cholesterol control.
  • Racial and ethnic disparities in glycemic control persisted among insured individuals.
  • Gender disparities were particularly noted in lipid control.

Why it matters

Understanding the role of health insurance in diabetes care quality is crucial for addressing ongoing disparities. This knowledge can inform policy decisions aimed at improving access and outcomes for vulnerable populations.

Source

PubMed · PMID 42380557Free full text on PubMed Central

Published in J Gen Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.